How is an "option to license" good news? What Amarantus is saying is that "we aren't quite sure the science is sound yet but if it pans out, we'll have first crack to license it." It's only good news if P16 amounts to something and that might take longer than 12 months. Expect a PR in the next 12 months about "extending" that license if the data doesn't come out as quickly as they hope. And what provisions in the agreement are there for the University to back out if they want? What's in the fine print of that agreement (something we'll never be able to read or know about).

I am still waiting to see if Lympro is even still viable. The company put some serious doubt into the test yesterday with their lackluster presentation.